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Huntington’s disease (HD) is an autosomal dominant 
neurodegenerative disease caused by a CAG repeat 
mutation in exon 1 of the HD gene. This repeat 
expansion leads to an extended polyglutamine tract in 
the huntingtin (htt) protein. Symptoms of HD are 
associated with hyperkinectivity and include chorea as 
well as other motor abnormalities. Degeneration is most 
apparent in a region of the striatum called the caudate 
putamen. Loss of GABAergic spiny projection neurons 
in this area leads to motor problems. My lab has made 
significant contributions to the understanding of HD by 
developing the commonly used R6/2 transgenic mouse 
model. The development of this model has led to our 
discovery of htt protein aggregates in mice and humans, 
which are presumably associated with 
neurodegeneration and compromise of the degradation 
pathway. Evidence suggests that mutant htt alters gene 
transcription factors (CREB binding protein, and SP1), 
p53 dependent apoptosis, transport of BDNF, 
interactions with caspases and proteasomes, as well as 
mitochondrial function. Treatment strategies include 
environmental enrichment, anti-apoptosis drugs, and 
gene therapy. While a cure for HD remains to be 
uncovered, newly proposed mechanisms of toxicity 




Huntington’s disease (HD) is a neurodegenerative disorder 
that is characterized by the misfolding and subsequent 
aggregation of a particular protein as is the case in many 
other neurodegenerative disorders, such as Parkinson’s 
disease, Alzheimer’s disease, and prion diseases. HD 
affects approximately 5-10 people per 100,000, making it the 
most common inherited neurodegenerative disorder. The 
protein in question in HD is Huntingtin (htt). The misfolding of 
this protein is believed to be caused by a mutation in exon 1 
of the IT15 gene located on chromosome 4. The mutation is 
a trinucleotide repeat; this characterizes HD as a member of 
triplet diseases, which is caused by an excessive amount of 
repeats in a gene (1). One of the first identified trinucleotide 
repeat diseases is fragile x syndrome, caused by an 
abnormal amount of CGG repeats in a particular gene. The 
group of nucleotides that is expanded in HD is CAG. This 
sequence codes for the amino acid glutamine in the htt 
protein. An expansion of the CAG sequence in the HD gene 
leads to a longer stretch of glutamines, termed a 
polyglutamine (polyQ) region.  
The number of CAG repeats determines toxicity. 
Individuals with 35 repeats or less do not develop the 
disease, whereas those with 36-39 have an increased risk of 
developing the disease. When the number of repeats is over 
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39 disease will develop, usually with symptoms presenting 
themselves between 35 and 50 years of age. An extreme 
form of HD also exists when the number of repeats is over 
60, leading to juvenile onset of HD. Number of CAG repeats 
in the polyQ tract is inversely related with age of disease 
onset. There are several other polyQ disorders caused by 
mutations on different chromosomes, such as certain types 
of spinocerebellar ataxias (SCA), dentatorubral 
pallidoluysian atrophy (DRPLA), and spinal and bulbar 
muscular atrophy (SBMA). Like HD these follow autosomal 
dominant patterns of inheritance and are disorders 
characterized by problems with movement (2). Symptoms of 
HD have an emotional, cognitive, and motor component and 
are associated with hyperkinectivity. They can range from 
being barely noticeable to extremely severe. Chorea is a 
characteristic symptom and is defined as spontaneous, 
irregularly timed, randomly distributed, and abrupt movement 
(1). Other frequently observed motor abnormalities include 
sustained muscle contraction, rigidity, and tremor. The 
emotional disorder usually consists of depression and 
irritability, and the cognitive component compromises a 
subcortical dementia. The main region of the brain affected 
by HD is the striatum, specifically the caudate nucleus and 
putamun. Neurons lost in these regions are primarily -
aminobutyric acid (GABA) releasing medial spiny projection 
neurons. Not only do neurons in this region show high levels 
of cell death, but protein aggregates termed intranuclear 
inclusions (NIIs) are also prevalent. Aggregates, believed to 
be a result of the incorrect folding of htt, while usually 
presenting themselves in the nucleus, can also be found in 
the cytoplasm of the cell (3).  
The exact function of wild type htt is yet to be 
determined, but evidence suggests its involvement in vesicle 
transport, neuronal transport, endocytosis, and postsynaptic 
signaling. The protein is ubiquitously expressed and is 
localized in many subcellular compartments (2). The 
mutation occurring in the HD gene presumably leads to a 
gain of function in the mutant htt rather than a loss of 
function. This is based on the evidence that HD knockout 
mice die neonatally due to abnormal brain development.   
My lab and other colleagues have conducted studies 
showing that mutant htt may impair the transcription of 
specific genes found in htt aggregates, such as p53, CREB 
binding protein, and Sp1. Evidence for impairment of the 
ubiquitine-proteasome system (UPS) is also shown by the 
accumulation of chaperones, proteasomes, and ubiquitin in 
polyQ aggregates.  
This paper will focus on the development of an 
animal model of HD which allowed for many of the 
aforementioned discoveries to be made.  The importance of 
these findings in identifying the molecular mechanisms 
underlying the steps between polyQ expansions and 
aggregate toxicity will be discussed as well as current and 
future treatment options. 
 
A mouse model and discovery of aggregates 
 
In the mid to late 90’s the main goal in my lab was to 
establish an efficient model of HD in order to better study the 
disease. After an initial attempt to construct an artificial 
chromosome in mutant yeast for injection into a murine 
model failed, a different approach was taken. We created 
several lines of mice that were transgenic for exon 1 of the 
human HD gene located on chromosome 4. By 
microinjecting this DNA fragment into mouse embryos, mice 
developed with a variety of different polyQ lengths. This 
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fragment was sufficient to produce a progressive 
neurological phenotype that displays many HD 
characteristics. Four transgenic lines were established; one 
of these lines, the R6/2 line carrying 144 CAG repeats was 
the most successful and was established as a disease 
model (1). 
Initially we were only able to detect several 
changes in R6/2 mouse brains that corresponded to human 
degeneration. Behavioral symptoms of HD present 
themselves at approximately 6 weeks of age. These include 
decreased motor function and a characteristic feet-clasping 
posture when suspended by their tails. R6/2 mice have a 
decreased size and body weight as well as decreased 
overall brain size. In a subsequent experiment we detected 
the presence of intranuclear inclusions (NIIs) in most brain 
regions; however, they were localized primarily in the 
cerebral cortex, cerebellum, and striatum (3). Extranuclear 
htt aggregates were observed as well. These are 
immunopositive for htt and are never found in control 
animals. In controls immunoreactivity for htt is in the 
cytoplasm. This suggests that wild type htt normally does not 
exist in the nucleus of cells. Aggregates can be observed as 
early as 3.5 weeks, showing that their formation precedes 
symptoms of neurodegeneration. Mice in all of the 
transgenic lines that exhibit symptoms have NIIs. This 
strongly implicates a causative role for NIIs in the generation 
of neurological dysfunction. I was very excited to discover 
that the presence of NIIs was shown in human postmortem 
tissue as well (4). While other studies reported change in 
neuronal membranes, such as the increase in nuclear 
indentation and the increase of nuclear pores, the presence 
of NIIs had not previously been detected. We were also able 
to show that R6/2 mice exhibit death of GABAergic neurons 
in the striatum, but this pathology does not present itself until 
approximately 13 weeks of age, the age around which R6/2 
mice usually die. The fact that inclusion body formation 
precedes degeneration of the striatum also indicates that 
aggregate formation might induce cell death. Another finding 
that supports this notion is that NIIs are ubiquitinated. This 
suggests that mutant htt protein is targeted for proteolysis 
and degradation but is resistant to removal (5). After the 
identification of NIIs in our mouse model and human HD 
tissue, we sought to develop an in vitro model as well. Exon 
1 of the human HD gene was used again to produce 
glutathione S-transferase (GST)-HD fusion proteins in E.coli. 
This resulted in the formation of high molecular weight 
protein aggregates. The filaments of these proteins have a 
ribbon-like morphology, which resembles both scrapie prions 
and -amyloid fibrils in Alzheimer’s disease. Additionally, 
these proteins are similar in appearance to aggregates 
detected by electron microscopy in R6/2 mice (5).   
Loss of neurotransmitter receptors in the brain is a 
pathologic hallmark of patients with HD. Receptors affected 
are glutamate receptors (GluR), dopamine (DA), GABA, and 
muscarinic cholinergic receptors (mAchR). Several 
neurotransmitter receptors known to be affected by HD are 
also decreased in R6/2 mice. These include several types of 
GluRs, mAchRs, as well as DA receptors, but do not include 
GABA receptors. The loss of GluRs is a particularly 
interesting finding since loss of presynaptic GluRs might 
result in the unregulated release of glutamate. Increased 
glutamate release has been thought to play a role in the 
pathogenesis of HD. While findings support the similarity of 
R6/2 mice to human HD, they cannot be explained by 




Figure 1. Biological Basis for Huntington Disease: An HD gene with expanded CAG repeats leads to mutant htt protein with an expanded polyQ 
region. This protein is unable to fold correctly. Consequent aggregation is associated with toxicity and neuronal death in the caudate putamen. 
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In order to confirm that mice of the R6/2 model 
suffered neurodegeneration in a way similar to humans, it is 
important to look at both characteristic pathological changes 
and changes in animal behavior indicative of motor 
impairment. As mentioned above, we observed that R6/2 
mice clasp their feet towards their body when suspended 
from their tails whereas non transgenic mice will hang freely. 
There have been several models prior to the development of 
the R6/2 line that showed motor symptoms of HD including 
abnormalities, gait, and impairments in sensorimotor gaiting. 
A model of importance was, and still is, the 3-nitropropionic 
acid (3-NP) model. However, because this model and others 
like it induce disease neurochemically, associated changes 
in behavior are not truly progressive. The R6/2 model, 
however, does allow for this. Our model showed that 
symptoms of behavioral changes can be observed as early 
as 5-6 weeks of age in tests that involve swimming, balance 
and motor coordination on beams, and footprint tests. 
Symptoms become obvious at around 8 weeks of age when 
mice display stereotypical hind limb grooming movements 
and an irregular gait. We have shown that symptoms 
progress and performance on tests decreases as mice age. 
A test called the RotaRod test is an effective way of 
measuring motor impairment and is commonly used not only 
in HD experiments but also in other diseases involving motor 
abnormalities, such as Parkinson’s disease and ataxias. The 
RotaRod test involves a rod suspended from the ground 
which can be set to different speeds, usually slightly higher 
than walking speed, on which mice have to walk. Mice are 
scored by how long they are able to remain on the rotating 
rod. Animals with severe motor impairments will not be able 
to remain on the rod for an extended amount of time. R6/2 
mice exhibit decreased performance on the RotaRod as they 
age, confirming that our model indeed induces progressive 
neurodegeneration (9). 
 
DNA instability and changes in synaptic function in R6/2 
model 
 
Once the R6/2 model of HD was established and we 
discovered the presence of htt aggregates, our lab and 
others were able to start using the model to study 
mechanisms by which neurodegeneration and aggregation 
occurs. The effectiveness of possible treatment options was 
also explored.  
One of the first findings we came across while 
establishing the mouse model was that there is DNA 
instability in the highly expanded CAG repeat ranges. CNS 
structures in particular are shown to exhibit the most 
variability in CAG repeat number. This change in repeat 
length is called somatic repeat instability. Repeat instability 
is shown to increase as mice age (10). More recently, we 
were able to show evidence for the same repeat instability in 
human tissue and that it is most evident in the striatum, 
cortex, and brain stem. Most importantly, we showed that 
these changes can occur in terminally differentiated neurons. 
Development of instability has been linked to the DNA 
mismatch repair pathway. Different mismatch repair genes 
have different effects on CAG repeat expansion. MSH3 is 
shown to be important in maintaining instability. Cells in 
which MSH3 is absent are unable to change CAG repeat 
size in adulthood (11). 
Knowing that substantial cell death does not occur 
in the R6/2 model until well after onset of symptoms, we set 
out to examine if other changes were occurring first. Human 
HD patients are also known to exhibit cognitive changes 
before classical symptoms of HD present themselves.  
Cognitive processes such as learning and memory are 
believed to be dependent on changes in synaptic function in 
certain brain regions, most importantly the hippocampus. We 
examined the baseline synaptic properties of the CA1 region 
of the hippocampus involved in cognition. Results suggested 
that normal synaptic transmission occurs in transgenic mice 
compared to control animals, but the mean amplitude of the 
action potential was significantly smaller in HD animals. 
Transgenic mice showed impairment in cognition when 
performing a cognition test called the Morris water maze. 
This indicates that altered synaptic plasticity may be 
contributing to the early cognitive deficit in presymptomatic 
HD patients (12). 
 
Transcription dysregulation in HD 
 
At this point we knew that NIIs were present in transgenic 
mice and HD patients, and we suspected their involvement 
in cell death. We were only able to prove this involvement 
after one important experiment showing that degeneration 
occurs in the same brain regions of transgenic mice and HD 
patients. More importantly,  the study showed that 
degeneration occurs specifically in the anterior cingulated 
cortex, striatum, and cerebellum. A more focused study of 
aggregates showed a temporal progression of protein 
aggregation, inclusion formation, appearance of symptoms, 
and finally neurodegeneration (12).  
In order for aggregation to take place several of 
the htt protein must undergo several changes. Normally, the 
htt protein is located in the nucleus.  A portion of the N’ 
terminal end of htt protein containing the polyQ expansion 
called httex1p is also localized to the nucleus, however, this 
is due to aberrant proteolytic cleavage of the protein. Htt 
interacts with the nuclear pore protein translocated promoter 
region (Tpr) which is involved in nuclear export. Mutant htt 
decreases the interaction with this protein and is therefore 
localized to the nucleus. Reducing expression of Tpr by RNA 
interference, or by deleting ten amino acids of N-terminal htt, 
which are essential for the interaction between htt and Tpr, 
increases the amount of htt in the nucleus (13). The 
consequences of nuclear localization of htt can be 
aggregation and errors in as well as suppression of gene 
transcription. Httexp1 is found to interact with the tumor 
suppressor protein p53 and CREB binding protein (CBP). 
Httexp1 prevents transcription of certain p53 activated 
promoters. CBP is a coactivator of several p53 regulated 
promoters. By direct sequestration of CBP to NIIs, mutant htt 
might repress transcription of these promoters. Changes in 
p53 expression can lead to changes in apoptosis since p53 
plays an important role in regulating this form of cell death 
(14). One experiment of ours indicated that cell death by 
apoptosis is not playing a role in the R6/2 model of disease. 
It could be that altered p53 transcription leads to a decrease 
in apoptosis in HD (15). An important paper by another lab 
showed further evidence of p53 interaction with mutant htt. 
Mutant htt upregulates levels of p53 throughout brains of HD 
mice and patients. Genetic deletion of p53 suppresses 
neurodegeneration in flies and neurobehavioral 
abnormalities in mice (16). 
A specific way that mutant htt interacts with the 
CREB-dependent transcriptional pathway is by inhibiting 
transcription of PGC-1, a coactivator that regulates several 
metabolic processes including mitochondrial synthesis and 
respiration. Inhibition of PGC-1 is associated with 
mitochondrial dysfunction. Moreover, induced expression of  
PGC-1 reverses the effects of mutant htt in cultures striatal 
neurons (17). 
There are several other known targets of htt-
mediated transcriptional repression. Another lab showed that 
the gene specific activator protein Sp1 is a direct target of 
mutant htt. TAF4 is one of the TATA binding protein 
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associated factors in TFIID. TFIID is one in a series of 
transcription initiating factors and is recruited to the core 
promoter with the help of Sp1. Another transcription factor is 
TFIIF. Two of its subunits RAP30 and RAP74 bind RNA 
polymerase and help recruit this enzyme to TFIID. In a 
normal situation the RAP30 interacts with RAP74 in order to 
function correctly. However, parts of hhtexp1 of mutant htt 
interact with the region of RAP30 that normally interacts with 
RAP74. Normal htt is shown to not interact with RAP30. The 
presence of free RAP74 is speculated to mediate toxicity 
and mechanisms that inhibit the transcription of certain 
genes. Overexpression of RAP74 leads to increased cell 
death in cultured mouse striatal cells whereas 
overexpression of RAP30 decreases cell death in the same 
type of culture (18). 
Another target of altered gene transcription is the 
cholesterol biosynthetic pathway. The transcription of genes 
in the cholesterol synthetic pathway is regulated via the 
activity of sterol regulatory element-binding proteins 
(SREBP’s). Cholesterol is synthesized in the brain and 
makes up a major component of myelin. It is also crucial for 
optimal neurotransmitter release, and a depletion of 
cholesterol can lead to a gradual loss of synapses. Reduced 
cholesterol levels have been shown to play a role in 
Alzheimer’s disease as well as Parkinson’s disease, and in 
an interesting experiment my lab showed up to a 50% 
decrease in the amount of SREBP’s in HD human and 
mouse brains. We showed that treatment of striatal neurons 
expressing mutant htt with exogenous cholesterol reduces 
cell death (19). This presents an interesting treatment option 
for HD.  
 
Impairment of the UPS system 
 
Another aspect of normal cellular function that is shown to 
be compromised in HD is the ubiquitin proteasome system 
(UPS). Proteasomes’ important function in the cell is to 
degrade damaged or incorrectly folded proteins. Proteins are 
tagged for degradation by a molecule called ubiquitin. 
Reduced function of the UPS system can lead to the 
presence of incorrectly folded proteins as is the case in HD. 
One molecule that my lab has shown to inhibit proteasome 
activity is arfaptin 2. Expression of arfaptin 2 is shown to be 
upregulated in sites of neurodegeneration. Arfaptin not only 
localizes to aggregates in HD mouse brains, it is also 
involved in regulating the aggregation of mutant htt. 
Increased expression of arfaptin results in increased 
aggregation by affecting the proteasome complex. 
Aggregates may in turn further harm the UPS system (20). 
Many other factors that may harm the UPS system 
have been discovered as well. For example, just last year we 
showed several changes in the ubiquitin system in cultured 
HD cells. Modification of proteins with polyubiquitin chains 
regulates important cellular processes, so it makes sense 
that altered ubiquitin signaling can have many effects on 
neuronal function and survival. We showed that the lys48 
linked polyubiquitin chain accumulates early in pathogenesis 
in R6/2 as well as human HD brains. Chains lys63 and 
lys11, which are not usually associated with proteosomal 
targeting, also accumulate in the R6/2 brain (21). 
SUMOylation is also shown to interact with httexp1. SUMO 
molecules can compete with ubiquitin to bind to httexp1. In 
this case the protein will not be marked for degradation as it 
would if tagged with ubiquitin. SUMOylation of httexp1 is 
thereby shown to promote neurodegeneration (22). Evidence 
against impairment of the UPS system has also been shown 
in my lab. We recently proposed that the proteasome 
activator REG could contribute to UPS impairment by 
inhibiting the cleavage of glutamine-glutamine bonds. When 
we genetically reduced REG levels in R6/2 mice, however, 
it did not change the well defined neurological phenotype or 
affect levels of NIIs (23). 
Two more important mechanisms involved in the 
progression of HD have been found. Caspase activity is one 
of them. As mentioned earlier, certain proteases cleave htt 
within the N-terminal region and this and expanded N-
terminal fragments lead to toxicity. Htt is cleaved by caspace 
3 and 6 in vitro, and fragments cleaved by these caspases 
are detectable in HD brains. Graham and colleagues 
showed in 2006 that cleavage of caspace 6, but not of 
caspace 3, is important in mediating neurodegeneration. 
Inhibition of caspace 6 in vivo was shown to significantly 
inhibit neurodegeneration (24). 
 
Chaperone proteins and changes in the cytoplasm 
 
A decrease in levels of chaperone proteins is another 
change that specifically leads to protein misfolding. Once 
information for proteins has been translated it is crucial that 
proteins fold correctly. Chaperone proteins help with such 
folding and also with the rescue of previously aggregated 
proteins. The manipulation of chaperone levels has been 
shown to inhibit aggregation and rescue cell death in several 
models of disease. For example, two chaperone proteins 
Hsp40 and Hsp70 have been shown to inhibit the 
aggregation of htt proteins with expanded polyQ tracts (25). 
My lab showed that the specific decrease of brain levels of 
chaperones Hdj1, Hdj2, Hsp70, SGT, and SGT 
contributes to disease pathogenesis and are therefore of 
importance in either the correction or prevention of mutant 
htt misfolding (26). 
Besides intranuclear aggregates, cytoplasmic 
degeneration can occur as well. My lab generated a line of 
mice in which nuclear localization or nuclear export signals 
were placed N-terminal to httexp1. Cytoplasmic 
degeneration was still shown to occur when a nuclear 
localization signal was present (27). Expression of a 
cytoplasmic polyQ repeat protein leads to axonal blockages 
in flies resulting in subsequent deficits in axonal transport. 
Nuclear htt causes cytoplasmic aggregation but not axonal 
blockages. This suggests that htt acts by two exclusive 
mechanisms, one that causes nuclear and cytoplasmic 
aggregation and another that leads to deficits in axonal 
transport (28). 
Deficits in axonal transport can lead to changes in 
transport of neurotransmitters (29). One example of a 
neurotransmitter whose transport is affected is BDNF. BDNF 
is produced in the striatum and is transported to the striatum. 
While deficits in BDNF are often associated with reduced 
BDNF transcription, another lab shows that BDNF transport 
is reduced by interaction with Huntingtin-associated protein 1 
(HAP1), which is important in regulating the microtubule-
based motor complex. By mutant htt interaction with HAP1, 
the motor machinery of mictrotubules is compromised which 
leads to reduced BDNF transport and subsequent 
neurotoxicity (30). Some others argue that full length htt can 
suppress neurodegenerative phenotypes and increase 
synaptic transmission of neurotransmitters (31).  
 
Possibilities for treatment and the role of the R6/2 model 
in development thereof 
 
There is currently no known cure for HD; the only drugs 
available are those that aim to alleviate symptoms. My lab 
and others have shown the importance of environmental 
enrichment in the R6/2 model. Transgenic animals that were 
in an enriched environment with a larger, warmer cage with 
different types of bedding, more toys, and more possibilities 
to exercise showed increased RotaRod performance as well 
as  an  increase  in  brain  weight  compared  to  animals in a  
 
 
Figure 2. A summary of well characterized action of mutant htt incuding transcriptional disregulation, UPS impairment, as well as intranuclear and 
cyroplamsic aggregation. 
 
normal, non-enriched cage (32,33). This has implications for 
human HD patients. An environment that is stimulating, 
particularly in academic and occupational attainment early 
on in life as well as throughout, may prevent a variety of 
diseases or delay their onset.  
Because caspase 6 is involved in cleavage of 
httexp1 of mutant htt, caspase 6 inhibitors are currently 
being explored as treatment options. My lab has also sought 
for molecules that inhibit polyQ aggregation. We found one 
molecule called C2-8 that was shown to inhibit aggregation 
in cell culture as well as a drosophila model of HD (34). 
Further investigation into the properties of this molecule is 
ongoing. It seems as though a combination of therapeutics 
would be the best approach to reduce symptoms of HD. 
From evidence brought forward in this paper we can propose 
that cholesterol treatment, expression of PCG-1, deletion of 
p53, and overexpression of certain chaperone proteins could 
be beneficial in treatment of HD. These treatments, however, 
could have possible negative effects as well, especially 
deletion of p53 which is often seen as the “guardian angel” 
of the cell.  
It is also important to explore different target 
treatments other than those that inhibit aggregation. Some 
researchers have found evidence that formation on NIIs 
might actually promote cell survival by grouping misfolded 
proteins together rather than having them diffuse throughout 
the cell (35). It is important to be extremely careful and 
critical when researching treatment options. This involves 
proper use and understanding of the R6/2 model. For 
example, the widely used tetracycline antibiotics, were 
explored as treatment options since they are inhibitors of 
certain caspases. Two closely related compounds 
minocycline and doxycycline were examined because they 
are able to cross the blood brain barrier. In one experiment 
minocycline was shown to be beneficial in the R6/2 model. 
There were no effects on aggregation, but improvement in 
RotaRod performance was observed. I want to stress the 
fact that while behavioral evidence is useful to support 
pathological evidence of improvement it is not to be used 
alone. An experiment with no reduction in cell death or 
aggregation cannot be said to be a success. We tested 
effects of minocycline and doxycycline ourselves but did not 
observe any pathological improvement either (36). It is also 
important to realize that the R6/2 model only contains exon 1 
of the human HD gene. If one wants to examine the effects 
of full length htt, HD knock in models will need to be used. 
Also, the R6/2 model is an accelerated model of disease 
which induces HD early on in the life of a mouse. The 
amount of 144 CAG repeats which R6/2 mice have is 
enough to induce juvenile HD in humans. Because this is an 
extreme situation, the accelerated phenotype of this model 
might not be able to detect subtle improvements due to 
therapy (37). Having said this, the R6/2 model can continue 
to be beneficial in the discovery of HD mechanisms and the 
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